Michael Mareska, MD
Neurology · Columbia, SCNPI 1538130778
Payments from drug & device makers
Across 96 payments — averaging $19.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Supernus Pharmaceuticals, Inc.$189
- Amgen$185
- Novartis$176
- Sanofi$153
- Teva Pharmaceuticals USA, Inc.$145
- Axsome Therapeutics, Inc.$96
- plus $959 from 27 others
What the payments were for
- Speaking & faculty fees$382%
- Food & beverage$1,85197%
- Education$121%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Supernus Pharmaceuticals, Inc. | 12 | $189 |
| Amgen | 4 | $185 |
| Novartis | 12 | $176 |
| Sanofi | 2 | $153 |
| Teva Pharmaceuticals USA, Inc. | 7 | $145 |
| Axsome Therapeutics, Inc. | 1 | $96 |
| EMD Serono, Inc. | 4 | $77 |
| AbbVie | 5 | $76 |
| Acadia Pharmaceuticals Inc | 4 | $71 |
| AstraZeneca | 2 | $52 |
| Grifols USA, LLC | 2 | $51 |
| Eisai Inc. | 3 | $50 |
| UCB, Inc. | 3 | $49 |
| TG Therapeutics, Inc. | 2 | $49 |
| Assertio Therapeutics, Inc. | 3 | $43 |
| Arbor Pharmaceuticals, Inc. | 3 | $42 |
| Acorda Therapeutics, Inc | 2 | $38 |
| Sunovion Pharmaceuticals Inc. | 4 | $38 |
| Amneal Pharmaceuticals LLC | 3 | $37 |
| MDD US Operations, LLC | 2 | $31 |
| Genentech USA, Inc. | 2 | $30 |
| Lilly USA, LLC | 2 | $28 |
| SK Life Science, Inc. | 1 | $28 |
| Argenx US, Inc. | 1 | $28 |
| Avanir Pharmaceuticals, Inc. | 2 | $24 |
| Bayer | 1 | $21 |
| Upsher-smith Laboratories LLC | 1 | $20 |
| Aquestive Therapeutics, Inc. | 1 | $15 |
| Pfizer | 1 | $15 |
| Promius Pharma LLC | 1 | $12 |
| Impel Pharmaceuticals Inc. | 1 | $12 |
| Livanova USA, Inc. | 1 | $11 |
| Dynasplint Systems Inc. | 1 | $10 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AIMOVIG$122
How this compares
$1,901 in reported general payments places this provider in the 55th percentile of 270 neurology providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Kesimpta PenOfatumumab | 42 | $417,581 |
| IngrezzaValbenazine Tosylate | 23 | $185,525 |
| BetaseronInterferon Beta-1b | 19 | $179,740 |
| Rebif RebidoseInterferon Beta-1a/Albumin | 15 | $153,888 |
| VimpatLacosamide | 82 | $104,186 |
| PlegridyPeginterferon Beta-1a | 11 | $91,106 |
| FycompaPerampanel | 64 | $81,225 |
| Nurtec OdtRimegepant Sulfate | 52 | $80,760 |
| KeppraLevetiracetam | 28 | $63,200 |
| Lacosamide | 548 | $62,547 |
| Aimovig AutoinjectorErenumab-Aooe | 38 | $42,260 |
| BriviactBrivaracetam | 28 | $38,721 |
| Levetiracetam | 622 | $32,265 |
| Teriflunomide | 25 | $31,491 |
| UbrelvyUbrogepant | 14 | $24,524 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| BayerBetaseron | $21 | $179,74019 claims |
| UCB, Inc.Vimpat, Briviact, Neupro | $49 | $152,623122 claims |
| Eisai Inc.Fycompa | $50 | $81,22564 claims |
| PfizerNurtec Odt | $15 | $80,76052 claims |
| AbbVieUbrelvy | $76 | $24,52414 claims |
| Amneal Pharmaceuticals LLCMycophenolate Mofetil, Pyridostigmine Bromide | $37 | $8,69861 claims |
| Upsher-smith Laboratories LLCTopiramate | $20 | $2,12896 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 270 neurology providers in South Carolina.
Other neurology in Columbia
- William McElveenColumbia$3.7M
- Eleanya Ogburu-OgbonnayaColumbia$137K
- Joseph FerraraColumbia$99K
- David HammettColumbia$86K
- Davit MrelashviliColumbia$70K
- Pradeep BolluColumbia$55K
- Miroslav CuturicColumbia$27K
- Mary HughesGreenville$6.3M
- Robert CarlileSummerville$2.3M
- Andrew KeeganCharleston$2.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.